NR3C1 and uterine corpus leiomyoma: Moreover, mifepristone, which is a competitive antagonist at both PR and GR with more than 3 times greater binding affinity for GR than DEX (15), inhibits extracellular matrix (ECM) formation in uterine leiomyoma (2).